BIR Theranostics Series: Prostate Cancer

5th February 2018  08:30 - 17:30 (GMT+00:00) GMT

Attend this course to discover an integrated approach to imaging in the diagnosis and treatment of prostate cancer. Our renowned international multidisciplinary faculty of expert oncologists, surgeons, radiologists and nuclear medicine physicians will provide a comprehensive overview of imaging technology and therapies. Attendees will develop their skills in the management of prostate cancer with talks covering radiological imaging, PET/CT, radionuclide therapy, early stage diagnosis and hormone sensitive advanced prognosis. There will also be opportunities for case-based discussions with our expert panel.
This meeting will be of interest to all nuclear medicine physicians, radiologists, oncologists, onco-surgeons, trainees, clinical physicists, technologists and health-care managers.
This is first of the BIR Theranostics Series in collaboration with the Nuclear Medicine faculty from the Royal Free London NHS Foundation Trust and University College London Hospitals NHS Foundation Trust.

View the full programme 

Registration fees
BIR Plan 1 member £165
BIR Plan 2 member £125
BIR Trainee member £75
BIR Retired member £65
BIR Student member £65
Non-member £275




We are very grateful to the following organisations for supporting this event.

Bayer Healthcare

The NHS faces many challenges today around the increasing need for governance to demonstrate best patient care within increasing financial constraints. Bayer’s Radiology business is well placed to be the partner in helping trusts to address these challenges. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 01635 563999

Blue Earth Diagnostics

Headquartered in Oxford, UK, Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative radiopharmaceuticals.


Hermes Medical Solutions


Micropos Medical

Micropos Medical is a Swedish medical device company with technology for enhanced radiotherapy of prostate cancer, like using hypofractionation and SRS/SBRT protocols. RayPilot® is a real time tumor tracking system that works with existing linacs to enable increased precision and less damage on surrounding healthy tissue.

Oncology Systems Limited

Philips Healthcare

Philips Healthcare is a leading supplier of diagnostic imaging systems and related services. Following the recent programme of acquisitions the company offers a comprehensive porfolio of healthcare products including conventional X-ray systems, dedicated systems for cardiovascular and interventional procedures; CT and MRI scanners, nuclear medicine, radiation therapy planning, echocardiography, digital ultrasound, patient cardiac monitoring equipment and PACS.

Siemens Healthcare

The healthcare market is in ongoing transition and we see healthcare providers worldwide drive consolidation, an increasingly "industrial" logic of healthcare delivery, and a shift from treating illness to managing health – ultimately looking for ways to improve outcomes while reducing costs. We aspire to be the partner to help achieve this goal. To live up to our ambition, we are determined to answer the questions that drive your business development. To overcome lack of specialised staff, ensure consistent outcomes across an organisation, increase competitiveness, avoid profitability risks, and implement growth strategies, we are your partner that you can rely on to stand out with clinical excellence, operational efficiency, and financial profitability.